2024 HCPCS Code G0429
Dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (lds) (e.g., as a result of highly active antiretroviral therapy)
TAGS: antiretroviral dermal facial treatment result filler lipodystrophy syndrome highly active
| Short Description | Dermal filler injection(s) |
| HCPCS Coverage Code | C - Carrier judgment |
| HCPCS Action Code | N - No maintenance for this code |
| HCPCS Action Effective Date | January 01, 2017 |
| HCPCS Code Added Date | March 23, 2010 |
| HCPCS Pricing Indicator Code | 13 - Price established by carriers (e.G., not otherwise classified, individual determination, carrier discretion) |
| HCPCS Multiple Pricing Indicator Code | A - Not applicable as HCPCS priced under one methodology |
| HCPCS Coverage Issues Manual Reference Section Number | |
| HCPCS Type Of Service Code | 1 - Medical care |
| HCPCS Anesthesia Base Unit Quantity | 0 |
Check Similar HCPCS Codes
- G9010 - Mccd, risk adj, level 4
- G9011 - Mccd, risk adj, level 5
- G9012 - Other specified case mgmt
- G9013 - Esrd demo bundle level i
- G9014 - Esrd demo bundle-level ii
- G9016 - Demo-smoking cessation coun
- G9017 - Amantadine hcl 100mg oral
- G9018 - Zanamivir,inhalation pwd 10m
- G9019 - Oseltamivir phosphate 75mg
- G9020 - Rimantadine hcl 100mg oral
- G9033 - Amantadine hcl oral brand
- G9034 - Zanamivir, inh pwdr, brand
- G9035 - Oseltamivir phosp, brand
- G9036 - Rimantadine hcl, brand
- G9037 - Intrpro req fr rec phys/qhcp
- G9038 - Co-management services
- G9050 - Oncology work-up evaluation
- G9051 - Oncology tx decision-mgmt
- G9052 - Onc surveillance for disease
- G9053 - Onc expectant management pt